Collecting data on neurodegenerative diseases progression markers
Official title: Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
Run by IRCCS San Raffaele Roma · NCT06596746 · Data updated 2026-11-12
This study is trying to find new signs that can help doctors understand how neurodegenerative diseases like Parkinson's progress, so they can improve early treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | IRCCS San Raffaele Roma Academic / other |
| Locations | 1 site (Cassino, Frosinone) |
| Status | Recruiting |
| Started | September 9, 2024 |
| Main results expected | September 9, 2034 |
| Study ends | September 9, 2034 |
| Registry record updated | September 2, 2026 |
| Trial ID | NCT06596746 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients diagnosed with Parkinson's Disease, Multiple System Atrophy, Lewy Body Dementia, and other related movement disorders.
✕Probably not a fit
Patients with neurodegenerative diseases not meeting the specific diagnostic criteria or those unwilling to participate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
MARKERS-NDD is a prospective, observational study that collects longitudinal data from patients with neurodegenerative diseases, including Parkinson's Disease and related disorders. The study involves routine clinical evaluations, movement analysis, brain imaging, neuropsychological assessments, and blood tests. The collected data will be analyzed using statistical methods and artificial intelligence to identify new early markers for diagnosis and prognosis of these diseases. This approach aims to improve the understanding of disease progression and enhance early intervention strategies.
Why it matters
Potential benefit: If successful, this study could lead to the identification of early diagnostic markers that improve patient outcomes in neurodegenerative diseases.
How similar studies have gone: Other studies have shown promise in using similar observational approaches to identify biomarkers in neurodegenerative diseases, indicating that this methodology has potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders
* Patients with diagnosis of Parkinson's Disease
* Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank
* Diagnosis of Movement Disorder not related to Parkinson's Disease
* Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;
* Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;
* Diagnosis of Essential Tremor
* Willing to participate in the study, understand the procedures and sign the informed consent.
* Patients affected by cognitive impairment (CI) and dementia
* Diagnosis of probable:
* Lewy Body Dementia
* Alzheimer's Disease
* Mild Cognitive Decline
* Subjective memory complaints
* Willing to participate in the study, understand the procedures and sign the informed consent.
Exclusion Criteria:
* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.
Where it's running
-
San Raffaele Cassino
Cassino, Frosinone, Italy Recruiting
Study contacts
- Study coordinator: Maria Francesca De Pandis, MD, PhD, Neurologist
- Email: maria.depandis@sanraffaele.it
- Phone: 0776394740
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biobank for studying ALS and Alzheimer's diseases
This study is collecting blood, skin samples, and health information from people to see how genetics might help us understand and find treatments for ALS and Alzheimer's disease.
-
A study on early diagnosis and biomarkers for dementia and related diseases
This study is testing new ways to spot dementia and related diseases early by looking for specific markers in the brain and body, to help people at high risk and track how well new treatments are working.
-
Treatment for neurologic disorders using stem cells
This study is testing whether using stem cells from patients' own bone marrow can help improve brain and nerve function in people with serious neurologic disorders that don't respond well to regular treatments.
-
Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes
This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.
-
Comparing protein patterns in skin biopsies of neurodegenerative diseases
This study is trying to see if the patterns of certain proteins in skin samples can help doctors better understand and diagnose different neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia.
-
Effects of speech-language intervention on bilingual speakers with primary progressive aphasia
This study tests if special speech therapy designed for bilingual people can help those with primary progressive aphasia communicate better in both of their languages.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.